News | February 10, 2026
SMS Pharmaceuticals posts strong Q3 with 29% PAT growth, full-year targets on track
The company’s EBITDA margin remained resilient above 20%
The company’s EBITDA margin remained resilient above 20%
Profit After Tax (PAT) for the quarter ended December 31, 2022 was at Rs. 290.8 crore as compared to Rs. 239.8 crore in the previous corresponding quarter, registering a growth of 21.3% YoY
The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives
With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
With launches, continuing momentum in India, other branded markets and a pick-up in the US, Ajanta would deliver 12% revenue/PAT growth each over FY22-24
Subscribe To Our Newsletter & Stay Updated
